Abstract

BackgroundAcute lymphoblastic leukemia (ALL) contains cytogenetically distinct subtypes that respond differently to cytotoxic drugs. Therefore, subtype classification is important and indispensable in ALL diagnosis. In our previous study, we identified some marker genes in childhood ALL by means of microarray technology and, furthermore, detected the relative expression levels of 57 marker genes and built a comparatively convenient and cost-effective classifier with a prediction accuracy as high as 94% based on the advanced fragment analysis (AFA) technique.MethodsA more convenient improved AFA (iAFA) technique with one-step multiplex RT-PCR and an anti-contamination system was developed to detect 57 marker genes for ALL.ResultsThe iAFA assay is much easier and more convenient to perform than the previous AFA assay and has a prediction accuracy of 95.29% in ALL subtypes. The anti-contamination system could effectively prevent the occurrence of lab DNA contamination. We also showed that marker gene expression profiles in pediatric ALL revealed 2 subgroups with different outcomes. Most ALL patients (95.8%) had a good-risk genetic profile, and only 4.2% of ALL patients had a poor-risk genetic profile, which predicted an event-free survival (EFS) of 93.6 ± 1.3% vs 18.8 ± 9.8% at 5 years, respectively (P < 0.001).ConclusionsCompared to the previous AFA assay, the iAFA technique is more functional, time-saving and labor-saving. It could be a valuable clinical tool for the classification and risk stratification of pediatric ALL patients.

Highlights

  • Acute lymphoblastic leukemia (ALL) contains cytogenetically distinct subtypes that respond differently to cytotoxic drugs

  • This is exemplified in how risk classification and corresponding chemotherapy have improved the outcome for patients with pediatric acute lymphoblastic leukemia (ALL)

  • Results improved AFA (iAFA) assay optimization for pediatric ALL subtypes The iAFA assay was carried out using our previous method, and the 57 marker genes were randomly divided into 3 panels, with each panel containing 18 to 20 genes [14]

Read more

Summary

Introduction

Acute lymphoblastic leukemia (ALL) contains cytogenetically distinct subtypes that respond differently to cytotoxic drugs. Genomic profiling has revolutionized our understanding of cancer and refined the classification of patients into clinically relevant subgroups [1]. This is exemplified in how risk classification and corresponding chemotherapy have improved the outcome for patients with pediatric acute lymphoblastic leukemia (ALL). Certain high-risk pediatric ALL subgroups remain relatively intractable to treatment, and many patients who relapse face a dismal outcome. Reliable classification and stringent risk assessment have become extremely important issues to improve the survival of patients at high risk and decrease the long-term treatment-related side effects in standard-risk patients [2,3,4,5]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call